Ma Songjiang 4
4 · GYRE THERAPEUTICS, INC. · Filed May 27, 2025
Insider Transaction Report
Form 4
Ma Songjiang
DirectorPresident
Transactions
- Sale
Common Stock
2025-05-22$10.97/sh−2,000$21,940→ 2,808,824 total(indirect: By Spouse) - Sale
Common Stock
2025-05-23$10.24/sh−182$1,864→ 2,808,642 total(indirect: By Spouse)
Footnotes (3)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.215 to $11.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.